Skip to content

Yam extract study for dementia

A placebo-controlled, randomized, double-blind study to evaluate the efficacy of yam extract for mild cognitive impairment and mild Alzheimer's disease

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs041200036
Enrollment
50
Registered
2020-07-21
Start date
2020-12-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild cognitive impairment and mild Alzheimer's d isease

Interventions

Intake of Yam extract
Yam extract

Sponsors

Suzuki Michio
Lead Sponsor
Tohda Chihiro
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Those whose age at consent date is 40 years - 85 years. 2) Those who can participate in the inspection performed at the University of Toyama Sugitani campus. 3) Those who meet the criteria for mild cog nitive impairment or mild Alzheimer's disease according to DSM-5. For patients with mild Alzheimer's disease, those who are taking only cholinesterase inhibitors. 4) Those who have MMSE score of 20 or more at the time of screening . 5) Those who ag ree to provide blood samples for clinical tests. 6) The person can take the test drug , and the person or family can manag e the medication of the test drug. 7) Those who agree not to take commercially available yam extract products during the test period. 8) Those who ag ree not to make any extreme chang es in lifestyle habits such as exercise and eating habits during the test period.

Exclusion criteria

Exclusion criteria: 1) Patients in the neurodevelopmental disorder, schizophrenia spectrum disorder and other psychotic disorders, bipolar disorder and related disorders, eating behavior disorder and eating disorder, personality disorder group. 2) Those who was in uncontrolled and clinically problematic health conditions (diabetes, hypertension, thyroid / endocrine disorders, cong estive heart failure, angina, heart disease, cancer risk such as breast cancer, uterine cancer, or ovarian cancer, gastrointestinal disease, dialysis or renal dysfunction, etc.) within 3 months of consent. 3) Those who have a history of alcohol and substance abuse 4) Those who have a history of yam allergy 5) Those who are participating in other invention clinical trials 6) Any other person who is judged to be inappropriate as a subject by the researcher

Design outcomes

Primary

MeasureTime frame
1) MMSE 2) ADAS-cog

Secondary

MeasureTime frame
1) Level of NF-L in plasma 2) Level of Abeta42 and Abeta40 in plasma for Abeta42/40 ratio 3) Level of GFAP in plasma

Contacts

Public ContactChihiro Tohda

University of Toyama

yamaimo@inm.u-toyama.ac.jp+81-76-434-7646

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026